辅助性T细胞17的表达对类风湿关节炎治疗的影响分析

Analysis of the effect of the expression of T helper 17 cells on the treatment of rheumatoid arthritis

目的:探讨辅助性T细胞17(Th17)的表达对类风湿关节炎(RA)治疗的影响。方法:选择2013年12月至2016年6月在本院诊治的78例活动期RA患者作为RA组,同期78例健康体检者作为对照组,两组都进行Th17的表达检测,同时进行细胞因子TGF-β、IL-6、IL-23、IL-17的血清表达检测与相关性分析。结果:RA组与对照组的Th17表达量分别为(4.98±1.39)%和(2.44±1.42)%,RA组明显高于对照组(P<0.05)。RA组的IL-17、IL-6和IL-23表达量均明显高于对照组(P<0.05),两组TGF-β表达量差异无统计学意义(P>0.05)。直线相关性分析显示,RA患者外周血Th17表达量与血清IL-17、IL-6与IL-23表达量呈明显正相关,而与TGF-β表达量无相关性;正规治疗组Th17的表达量明显低于非正规治疗组(P<0.05)。结论:Th17在类风湿关节炎患者中呈现高表达状况,可导致IL-17、IL-6与IL-23等细胞因子表达升高,能明确反映患者的治疗状况,有很好的应用价值。

Objective： To investigate the effect of T helper 17 cells （Th17） expression in the treatment of rheumatoid arthritis（RA）. Methods： From December 2013 to June 2016, 78 RA patients of our hospital for treatment were selected as the RA group, and 78 healthy people for health examination in our hospital at the same period were selected as the control group, two groups of Th17 expression were detected. At the same time, the serum cytokine TGF -, IL-6 and IL-23 and IL-17 expression were also given detection and correlation analysis. Results： The expression levels of Th17 in the RA group and control group were 4.98±1.39% and 2.44±1.42% respectively, and RA group was significantly higher than that in control group （P〈0.05）. The expression levels of IL-17, IL-6 and IL-23 in the RA group were significantly higher than those in control group （P〈0.05）, and there was no significant difference in the expression of TGF- compared between the two groups （P〉0.05）. Linear correlation analysis showed that in the RA patients, the peripheral blood Th17 expression level were significant positive correlated to the serum IL-17, IL-6 and IL-23 expression （P 〈 0.05）. The expression of Th17 in the regular treatment group was also significantly lower than that of non regular treatment group （P 〈 0.05）. Conclusion： Th17 in RA patients with high expression, IT can lead to IL-17, IL-6 and IL-23 and other cytokine expression are increased, it can clearly reflect the patient＇s treatment status that has a good application value.